Axsome Therapeutics announced the official results from its 2026 Annual Meeting of Stockholders held on June 5, 2026. All three proposals submitted to a vote were approved, including the election of two Class II directors, the ratification of the company's independent accounting firm, and the advisory approval of executive compensation.

Key Details

  • Director Election: Shareholders elected Mark Saad and Susan Mahony, Ph.D., MBA to serve as Class II directors until the 2029 annual meeting.
  • Auditor Ratification: The appointment of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
  • Executive Compensation: A non-binding advisory proposal to approve the compensation of the company's named executive officers was approved by shareholders.
  • Meeting Quorum: Approximately 85.10% of the shares entitled to vote were represented at the meeting, constituting a quorum.